Board of Directors | Consumer Health Activation | Welltok
page-template,page-template-full_width,page-template-full_width-php,page,page-id-519,stockholm-core-1.2.1,ajax_fade,page_not_loaded,,select-theme-ver-4.4.1,wpb-js-composer js-comp-ver-6.2.0,vc_responsive

Our Board of Directors

We’ve assembled one of the most experienced, successful and diverse boards of directors in the industry. Their deep experience ranges from healthcare IT, enterprise SaaS software and mobile development to consumer engagement technologies
Read Bio

Jeff served as CEO of Welltok for 7 years and is on the board of directors for TriNetX, NextGen Healthcare (NASDAQ: NXGN), Alignment Healthcare, Hoag Hospital, and University of California at Irvine’s Center for Digital Transformation. He is a recognized healthcare IT leader based on his 35-year track record of applying technologies to address the complex problems facing the healthcare industry.

Previously, Jeff founded and served as CEO of TriZetto, the leading healthcare management services company. He led TriZetto through a successful IPO and $1.4B private equity buyout. As a health futurist and visionary, Jeff is a frequent speaker, guest lecturer and author – with his 3rd book in development.

Read Bio

Stephen is a Partner at Bessemer and leads the firm’s healthcare investing activities.

He currently sits on the boards of Health Essentials, DocuTAP, Ovascience (NASDAQ: OVAS), Flex Pharma, Allena Pharmaceuticals and Alcresta, and he is actively involved in BVP’s investment in Clearcare.

Steve has also been actively involved in many Bessemer’s investments that have resulted in IPO or acquisition such as Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ:AFFY); and Restore Medical (NASDAQ: REST), acquired by Medtronic.

Steve was recognized by Forbes Magazine as one of the top healthcare investors in the industry.

Read Bio

Nina Kjellson is a General Partner at Canaan Partners focused on biopharmaceuticals and digital health investments.

Nina is an active board member of Eiger Biopharmaceuticals, Lycera and Ocera (NASDAQ: OCRX). She is also co-chair of, a mentor to the BluePrint Health Accelerator, and serves on the board of the California Family Health Council.

Read Bio

Kevin is General Partner at Emergence Capital. His deep knowledge of the enterprise and consumer technology sectors comes from time spent at blue chip companies, including Microsoft and Electronic Arts, and his experience as an entrepreneur.

Kevin spends a significant portion of his time working with digital health companies including Doximity, and Augmedix. He was also previously on the board of Veeva Systems. Kevin’s other investments include Handshake, VigLink and Zettics.

Read Bio

Khaled Nasr is the Chief Operating Officer of Interwest, and is responsible for all of the firm’s financial, fundraising, investor relations and administrative functions. He joined InterWest’s IT team in 2005 to invest in mobile, cloud and data center infrastructure, including systems, software and semiconductors.

His recent exited investments include Virsto Software (acquired by VMWare), NexPlanar (acquired by Cabot Microelectronics) and DataRPM (acquired by Progress Software).

Read Bio

Mohamad is a General Partner at NEA and heads the firm’s Healthcare Services and Healthcare Information Technology investment practice.

He is currently a Director of Aetion, American Pathology Partners, Bright Health, Collective Health, Curisium, Docent Health, Nuvolo, Pager, Paladina Health, Radiology Partners, SCI Solutions and U.S. Renal Care.

Mohamad is an active participant in the cancer community and a founding board member of Livestrong’s Young Leadership Cancer Council.

Read Bio

Regina Paolillo currently serves as Chief Financial Officer, Chief Administrative Officer, and Executive Vice President at TeleTech, a Colorado-based company that specializes in designing, building and operating omnichannel customer experiences on behalf of leading brands across the world.

At TeleTech, Regina leads all finance, treasury, and accounting functions, as well as the enterprise human capital, strategic sourcing, enterprise risk management and mergers and acquisitions teams.

Read Bio

Michael is a General Partner and Co-founder of Flare Capital Partners, an early-stage healthcare technology venture capital firm.

Some of his existing and prior board seats include Explorys, HealthVerity, Taris and T2 Biosystems.

In addition Michael serves on several association boards including the Industry Advisory Board for the Cleveland Clinic, the Investment Committee for the Partners Innovation Fund and was on the Executive Committee of the National Venture Capital Association.

Read Bio

Steve Leightell is a Principal on the investment team at Georgian Partners. He brings 20 years of software experience with operational expertise in channels, partnerships and strategy planning for acquisitions.

Steve sits on several boards as either a board director or board observer, including Data Candy, Cority, RiskIQ and Flashpoint. He also serves on the board of the Canadian Venture Capital Association.

Read Bio

Ellen Koskinas is the Managing Director of Hearst Health Ventures and leads the fund’s investing efforts. Her deep knowledge of healthcare comes from her operating experience at Guidant, where she started a new business which has grown to over $200MM in revenues, and her experience at McKinsey, consulting to leading health care organizations on key strategic and operational challenges.

Ellen is a board member of Tonic Health and also served on the board of CareInSync, prior to its acquisition by Zynx Health. Ellen has served as a frequent guest lecturer at Stanford University and on the Advisory Board of the Stanford Program in Healthcare Innovation.

Read Bio

Bruce Hallett is a Co-founder of Miramar Venture Partners and brings his enthusiasm for innovation, product strategy and team building to Miramar’s portfolio of tech startup companies. With over two decades of collaborations with technology entrepreneurs, Bruce leads Miramar investments in mobile Internet solutions and software.

Read Bio

Thomas is the head of health care investing at Qualcomm Ventures where he focuses on digital health care companies. Thomas is also a General Partner at dRx Capital, which is a joint venture investment company launched by Novartis and Qualcomm with a capital commitment up to $100M. As part of these roles, Thomas strives to catalyze the success of digital medicine products, services and business models by investing in high-growth, technology companies.

Prior to Qualcomm Ventures, Thomas was an investment professional at Providence Ventures, the venture capital arm at one of the nation’s leading healthcare delivery networks, Providence St. Joseph Health. Prior to Providence Ventures, Thomas was part of the strategic finance / strategic investing team at Cambia Health Solutions, the private equity sponsor for Regence Blue Cross Blue Shield, a nationally recognized health insurer committed to transforming healthcare. As part of his role at Cambia, Thomas had an observer seat on the Fund Management Team (FMT), the formal governing body established by the company to approve all VC, PE and M&A deals. Thomas was also a direct investment professional at Adams Street Partners where he supported the partnership on venture capital and growth equity opportunities.

Thomas holds his Master of Science in Medical Informatics and a Bachelor of Science in Biomedical Engineering from Northwestern University where he is a published author in the Journal of Surgical Oncology.